An important difference between PARP activation in cancer and that in pulmonary disease is that it is accompanied in tumours with up-regulation of NMPRT and also NMNAT, such that nicotinamide is continually recycled to NAD+, further enhancing PARP activity and providing NAD+ to the tumour in perpetuity. Here, PARP1 is linked to cancer.